These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 17395894)

  • 1. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
    J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.
    Childress AC; Berry SA
    Postgrad Med; 2010 Sep; 122(5):35-41. PubMed ID: 20861586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
    González MA; Campbell D; Rubin J
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule.
    Pentikis HS; Simmons RD; Benedict MF; Hatch SJ
    J Am Acad Child Adolesc Psychiatry; 2002 Apr; 41(4):443-9. PubMed ID: 11931601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
    Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
    Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
    Swanson J; Gupta S; Guinta D; Flynn D; Agler D; Lerner M; Williams L; Shoulson I; Wigal S
    Clin Pharmacol Ther; 1999 Sep; 66(3):295-305. PubMed ID: 10511066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder.
    Corkum P; Panton R; Ironside S; Macpherson M; Williams T
    J Pediatr Psychol; 2008 May; 33(4):368-79. PubMed ID: 18056144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D; Katic A; Buckwalter M; Webster K
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.